A droplet #microfluidics technology has been developed to measure #proteinsecretion kinetics from #singlecells. This technology has been successfully used to characterize monocyte anergy in septic shock patients. SharedIt link
BIOASTER welcomes the renewal of the support of the French Government. The Government thus strongly and clearly expresses its confidence in IRTs to develop and boost French technological research. This...
BIOASTER has entered into a collaboration agreement with Takeda to develop and validate new microbiome-based approaches in the context of Takeda’s clinical-stage assets for the treatment of gastrointestinal diseases. This...
A Covid-19 learning By Nathalie Garçon, CEO/CSO BIOASTER The current crisis reminds us today of the absolute and universal need to prepare in advance for such epidemics, which no...
@BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation @gatesfoundation to develop #Onchocerciasis advanced rapid #diagnostic with @mologic Ltd. BIOASTER, today announced it has received a grant in...
#OmicsTechnologies are today in the heart of early research in #microbiology and #InfectiousDiseases. To leverage these #technologies in applied research, we need to develop new solutions corresponding to industrial processes...
Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome. Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and...
BIOASTER announces a collaboration with Exeliom Biosciences, a leading biotech in the developement of innovative microbiome-based therapies, located in Paris and Dijon, France. The aim of the partnership is to...
Dynamiser la recherche sur le microbiote. Deux lauréats du Programme des Investissements d’Avenir (PIA), #Metagenopolis @INRA (démonstrateur pré-industriel, Lauréat 2012) et @BIOASTER (L’Institut de Recherche Technologique en microbiologie, Lauréat 2012),...
BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI),...
Debiopharm & BIOASTER join forces to expand research to combat infectious diseases. Debiopharm and BIOASTER announced having officialized a broad research agreement for the development of diagnostic and management innovation...
BIOASTER teams are currently in Utrecht for the kick-off meeting of the European project GNA-NOW, part of the AMR Accelerator Programme of IMI 2. We are proud to be part...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
